Progesterone Market

Market Overview The Global Progesterone Market is projected to experience growth, expanding from USD 226.13 Million in 2025 to USD 268.91 Million by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 2.93%. Progesterone, a naturally occurring steroid hormone, plays a vital role in regulating the menstrual cycle, sustaining pregnancy, and facilitating embryogenesis, finding commercial application in hormone replacement therapy (HRT) and assisted reproductive technology (ART). This market expansion is primarily driven by the increasing prevalence of infertility and a growing aging female demographic seeking clinical solutions for menopausal symptoms, further bolstered by renewed confidence in the safety profiles of hormonal treatments which has led to higher patient adoption rates. For instance, The Menopause Society reported a significant recovery in therapeutic uptake, with hormone therapy usage among women aged 40 to 60 increasing to 13% in 2025, reflecting evolving medical guidelines. Notwithstanding these growth catalysts, the market faces a considerable obstacle due to the potential health risks associated with long-term progesterone administration. Persistent safety concerns and increased regulatory scrutiny regarding adverse effects, particularly the heightened risk of breast cancer and cardiovascular complications linked to prolonged steroid hormone use, continue to generate apprehension among healthcare providers, thereby limiting the duration of treatment prescriptions. Market Driver The market for progesterone is significantly propelled by the expanding use of Assisted Reproductive Technologies (ART) and various infertility treatments, where progesterone administration is crucial for supporting the luteal phase and achieving successful pregnancies in In Vitro Fertilization (IVF) cycles. This dependency is intensifying as access to fertility services broadens globally, leading to a greater demand for diverse formulations including vaginal, injectable, and oral progesterone. This trend is evidenced by the Society for Assisted Reproductive Technology's April 2025 report, which indicated a substantial year-over-year increase, with the total number of IVF cycles performed at member clinics rising to 432,641 in 2023, directly correlating with higher therapeutic consumption. In response to this specific clinical need, manufacturers are innovating; for example, Besins Healthcare launched Prometrium 400mg soft vaginal capsules in the UK in April 2025, specifically licensed to prevent miscarriage in women experiencing early pregnancy bleeding. Furthermore, the rising global demand for Hormone Replacement Therapy (HRT) acts as a significant market driver, spurred by an aging female population seeking effective management for menopausal symptoms and long-term health maintenance. Within these regimens, progesterone is indispensable for women with an intact uterus, as it prevents estrogen-induced endometrial hyperplasia, thereby ensuring sustained long-term prescription renewal rates. This robust demand is reflected in considerable growth in prescription volumes across key markets; according to the NHS Business Services Authority's October 2025 'Hormone Replacement Therapy - England' report, the total number of HRT items prescribed increased by 11% from the previous year, reaching 14.7 million in 2024/25. Such substantial uptake underscores progesterone's lasting commercial relevance within established healthcare systems. Market Challenge A significant impediment to the Global Progesterone Market stems from the enduring health risks associated with prolonged hormone administration, specifically the elevated potential for breast cancer and cardiovascular complications. These safety concerns profoundly impact clinical decision-making, prompting healthcare providers to limit prescription durations and adopt more conservative treatment protocols. Consequently, this medical prudence curtails the potential for consistent revenue from long-term maintenance therapies, directly diminishing the overall global consumption volume of progesterone, as physicians prioritize patient safety over extended therapeutic regimens. The gravity of these concerns is further emphasized by current data illustrating the prevalence of hormone-sensitive malignancies, which sustains apprehension regarding extended steroid usage. The American Cancer Society estimated 316,950 new cases of invasive breast cancer in women in the United States in 2025. This substantial disease burden intensifies regulatory and clinical scrutiny surrounding hormone replacement therapies, compelling physicians to strictly enforce shorter treatment courses to minimize carcinogenic risks and, as a result, the market experiences a constrained growth trajectory, with the window for safe therapeutic application remaining tightly bounded by these overriding safety considerations. Market Trends The Global Progesterone Market is experiencing a definitive shift towards bioidentical micronized progesterone, fundamentally transforming the product landscape as both patients and clinicians increasingly favor formulations offering superior safety and tolerability compared to synthetic progestins. This preference is rooted in the clinical desire for molecules that structurally mirror endogenous hormones, thereby aiming to alleviate the perceived risks of breast cancer and venous thromboembolism historically linked with traditional synthetic alternatives. This commercial pivot is substantiated by the robust financial performance of companies specializing in these formulations, which are observing rapid revenue expansion from their bioidentical portfolios; for instance, Nasdaq reported in August 2025 that TherapeuticsMD's license revenue, significantly driven by its bioidentical hormone therapies, surged to $1.0 million in the second quarter of 2025, marking an impressive 334% increase from the prior year. Concurrently, the integration of progesterone distribution through telehealth and digital pharmacy channels is revolutionizing patient access, particularly as a strategic response to persistent regional supply chain disruptions. Digital platforms are emerging as crucial intermediaries, providing streamlined consultation-to-delivery models that circumvent traditional physical bottlenecks and enhance treatment adherence through convenient subscription-based services. This operational evolution is additionally bolstered by government initiatives aimed at reducing cost barriers and ensuring continuous care for menopausal women, which digital providers are actively capitalizing on to maintain consistent stock availability. As an example, UK Meds highlighted in January 2025 that the implementation of the HRT Prescription Prepayment Certificate has successfully facilitated affordable access for over 500,000 women, directly contributing to the stabilization of demand fulfillment via these modern dispensing corridors. Key Market Players * NAARI PHARMA Pvt. Ltd * La Chandra Pharmalab Pvt. Ltd. * BGP Laboratories Private Limited * Mankind Pharma Ltd * Bhugan Lifescience Pvt Ltd * Abcures Biosciences LLP * Symbiotec Pharmalab * Granth Pharma Pvt Ltd * Emote Lifesciences LLP Report Scope In this report, the Global Progesterone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Progesterone Market, By Sales Channel * Direct * Indirect # Progesterone Market, By End Use * Hormone Replacement Therapy * Infertility Treatment * Menstrual Disorders * Premenstrual Syndrome (PMS) * Others # Progesterone Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Progesterone Market. Available Customizations: Global Progesterone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).